JP4263240B2 - ５−フェニル−３−（ピペリジン−４−イル）−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体、及びその５−ｈｔ４又はｈ３レセプターリガンドとしての用途 - Google Patents
５−フェニル−３−（ピペリジン−４−イル）−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体、及びその５−ｈｔ４又はｈ３レセプターリガンドとしての用途 Download PDFInfo
- Publication number
- JP4263240B2 JP4263240B2 JP51791797A JP51791797A JP4263240B2 JP 4263240 B2 JP4263240 B2 JP 4263240B2 JP 51791797 A JP51791797 A JP 51791797A JP 51791797 A JP51791797 A JP 51791797A JP 4263240 B2 JP4263240 B2 JP 4263240B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- piperidin
- compound
- dihydro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003446 ligand Substances 0.000 title description 4
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- RJIHZTHWMPTLQL-UHFFFAOYSA-N 5-phenyl-3-piperidin-4-yl-1,3,4-oxadiazol-2-one Chemical class O=C1OC(C=2C=CC=CC=2)=NN1C1CCNCC1 RJIHZTHWMPTLQL-UHFFFAOYSA-N 0.000 title 1
- 102000004384 Histamine H3 receptors Human genes 0.000 title 1
- 108090000981 Histamine H3 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 91
- -1 2-ethoxy-2-oxoethyl group Chemical group 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 68
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 238000002844 melting Methods 0.000 description 44
- 230000008018 melting Effects 0.000 description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- 239000002904 solvent Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000002244 precipitate Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- RDTNHKAOMIMKAR-UHFFFAOYSA-N 5-(6-chloro-3,4-dihydro-2h-chromen-8-yl)-3-piperidin-4-yl-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C=1C(Cl)=CC=2CCCOC=2C=1C(OC1=O)=NN1C1CCNCC1 RDTNHKAOMIMKAR-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- SCWKRWCUMCMVPW-UHFFFAOYSA-N phenyl n-methylcarbamate Chemical compound CNC(=O)OC1=CC=CC=C1 SCWKRWCUMCMVPW-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RLKMOPWWGZKHOP-UHFFFAOYSA-N 1-butylpiperidin-4-ol Chemical compound CCCCN1CCC(O)CC1 RLKMOPWWGZKHOP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 3
- AYWZMFWXMUZADG-UHFFFAOYSA-N 5-(5-chloro-2,3-dihydro-1-benzofuran-7-yl)-3h-1,3,4-oxadiazol-2-one Chemical compound C=1C(Cl)=CC=2CCOC=2C=1C1=NNC(=O)O1 AYWZMFWXMUZADG-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 3
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- MKAOCOUXFNFMFN-UHFFFAOYSA-N 3-piperidin-4-yl-1,3,4-oxadiazol-2-one Chemical compound O=C1OC=NN1C1CCNCC1 MKAOCOUXFNFMFN-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- KLPBRQIQIHTCRI-UHFFFAOYSA-N 4-amino-5-chloro-2-(cyclopropylmethoxy)benzoic acid Chemical compound C1=C(Cl)C(N)=CC(OCC2CC2)=C1C(O)=O KLPBRQIQIHTCRI-UHFFFAOYSA-N 0.000 description 2
- RVEATKYEARPWRE-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxybenzoic acid Chemical compound COC1=CC(N)=C(Cl)C=C1C(O)=O RVEATKYEARPWRE-UHFFFAOYSA-N 0.000 description 2
- HQDKULCXUILIJK-UHFFFAOYSA-N 5-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-methylpiperidin-4-yl)-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.COC1=CC(N)=C(Cl)C=C1C(OC1=O)=NN1C1CCN(C)CC1 HQDKULCXUILIJK-UHFFFAOYSA-N 0.000 description 2
- IVAVPGIRMLIZIK-UHFFFAOYSA-N 5-(4-amino-5-chloro-2-methoxyphenyl)-3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one Chemical compound COC1=CC(N)=C(Cl)C=C1C(OC1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CC1 IVAVPGIRMLIZIK-UHFFFAOYSA-N 0.000 description 2
- SXNDHILBPJENQA-UHFFFAOYSA-N 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-(1-butylpiperidin-4-yl)-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C1CN(CCCC)CCC1N1C(=O)OC(C=2C=3OCCOC=3C(N)=C(Cl)C=2)=N1 SXNDHILBPJENQA-UHFFFAOYSA-N 0.000 description 2
- BQNIHLDTULCIEK-UHFFFAOYSA-N 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one Chemical compound C1=2OCCOC=2C(N)=C(Cl)C=C1C(OC1=O)=NN1C1CCN(CCCC(F)(F)F)CC1 BQNIHLDTULCIEK-UHFFFAOYSA-N 0.000 description 2
- YLUSJQXFXOEXCI-UHFFFAOYSA-N 5-(5-chloro-2,3-dihydro-1-benzofuran-7-yl)-3-piperidin-4-yl-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C=1C(Cl)=CC=2CCOC=2C=1C(OC1=O)=NN1C1CCNCC1 YLUSJQXFXOEXCI-UHFFFAOYSA-N 0.000 description 2
- VWMNFPMZOBFURK-UHFFFAOYSA-N 5-(6-chloro-3,4-dihydro-2h-chromen-8-yl)-3h-1,3,4-oxadiazol-2-one Chemical compound C=1C(Cl)=CC=2CCCOC=2C=1C1=NNC(=O)O1 VWMNFPMZOBFURK-UHFFFAOYSA-N 0.000 description 2
- ADILBXYZUSZGPV-UHFFFAOYSA-N 5-[4-amino-5-chloro-2-(cyclopropylmethoxy)phenyl]-3-(1-butylpiperidin-4-yl)-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C1CN(CCCC)CCC1N1C(=O)OC(C=2C(=CC(N)=C(Cl)C=2)OCC2CC2)=N1 ADILBXYZUSZGPV-UHFFFAOYSA-N 0.000 description 2
- UJRRAIJFGCLEBS-UHFFFAOYSA-N 5-[4-amino-5-chloro-2-(cyclopropylmethoxy)phenyl]-3h-1,3,4-oxadiazol-2-one Chemical compound N=1NC(=O)OC=1C=1C=C(Cl)C(N)=CC=1OCC1CC1 UJRRAIJFGCLEBS-UHFFFAOYSA-N 0.000 description 2
- KGEWUGWPCVDMCP-UHFFFAOYSA-N 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C1C(C(O)=O)=CC(Cl)=C2N KGEWUGWPCVDMCP-UHFFFAOYSA-N 0.000 description 2
- JVKROPCXEGJZRU-UHFFFAOYSA-N 5-chloro-1-[4-(dimethylamino)piperidin-1-yl]pentan-1-one Chemical compound CN(C)C1CCN(C(=O)CCCCCl)CC1 JVKROPCXEGJZRU-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 2
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- HLKRRQKWCIYCOW-UHFFFAOYSA-N ethyl 5-amino-2,3-dihydro-1,4-benzodioxine-8-carboxylate Chemical compound O1CCOC2=C1C(N)=CC=C2C(=O)OCC HLKRRQKWCIYCOW-UHFFFAOYSA-N 0.000 description 2
- DEIOKFOOELDPJF-UHFFFAOYSA-N ethyl 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylate Chemical compound O1CCOC2=C1C(N)=C(Cl)C=C2C(=O)OCC DEIOKFOOELDPJF-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- NSZVTEICVFGKFN-WLHGVMLRSA-N (E)-but-2-enedioic acid 5-(6-chloro-3,4-dihydro-2H-chromen-8-yl)-3-[1-[5-[4-(dimethylamino)piperidin-1-yl]-5-oxopentyl]piperidin-4-yl]-1,3,4-oxadiazol-2-one Chemical compound OC(=O)\C=C\C(O)=O.C1CC(N(C)C)CCN1C(=O)CCCCN1CCC(N2C(OC(=N2)C=2C=3OCCCC=3C=C(Cl)C=2)=O)CC1 NSZVTEICVFGKFN-WLHGVMLRSA-N 0.000 description 1
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- GZCJYYAZHWTDPB-UHFFFAOYSA-N 3-(1-butylpiperidin-4-yl)-5-(5-chloro-2,3-dihydro-1-benzofuran-7-yl)-1,3,4-oxadiazol-2-one Chemical compound C1CN(CCCC)CCC1N1C(=O)OC(C=2C=3OCCC=3C=C(Cl)C=2)=N1 GZCJYYAZHWTDPB-UHFFFAOYSA-N 0.000 description 1
- WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical compound O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 description 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- ASEQRNMSKNNTSN-UHFFFAOYSA-N 4-chloro-1-[4-(dimethylamino)piperidin-1-yl]butan-1-one Chemical compound CN(C)C1CCN(C(=O)CCCCl)CC1 ASEQRNMSKNNTSN-UHFFFAOYSA-N 0.000 description 1
- IIFPDBNYAVYPPD-UHFFFAOYSA-N 5-(4-amino-5-chloro-2-methoxyphenyl)-3-[1-(cyclohexylmethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one Chemical compound COC1=CC(N)=C(Cl)C=C1C(OC1=O)=NN1C1CCN(CC2CCCCC2)CC1 IIFPDBNYAVYPPD-UHFFFAOYSA-N 0.000 description 1
- MZLXFFYMEYFKIT-UHFFFAOYSA-N 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-1,3,4-oxadiazol-2-one Chemical compound C1=2OCCOC=2C(N)=C(Cl)C=C1C(OC1=O)=NN1C(CC1)CCN1CC1=CC=C(C(F)(F)F)C=C1 MZLXFFYMEYFKIT-UHFFFAOYSA-N 0.000 description 1
- WLWMWCGUHCKKOH-UHFFFAOYSA-N 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-piperidin-4-yl-1,3,4-oxadiazol-2-one Chemical compound C1=2OCCOC=2C(N)=C(Cl)C=C1C(OC1=O)=NN1C1CCNCC1 WLWMWCGUHCKKOH-UHFFFAOYSA-N 0.000 description 1
- ULHMLASICRQGFL-UHFFFAOYSA-N 5-(5-chloro-2,3-dihydro-1-benzofuran-7-yl)-3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C=1C(Cl)=CC=2CCOC=2C=1C(OC1=O)=NN1C(CC1)CCN1CCC1=CC=CC=C1 ULHMLASICRQGFL-UHFFFAOYSA-N 0.000 description 1
- CXTXQNHSWMSFLA-UHFFFAOYSA-N 5-(6-chloro-3,4-dihydro-2h-chromen-8-yl)-3-(1-propan-2-ylpiperidin-4-yl)-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCC1N1C(=O)OC(C=2C=3OCCCC=3C=C(Cl)C=2)=N1 CXTXQNHSWMSFLA-UHFFFAOYSA-N 0.000 description 1
- LPUPVNNWASFIFG-UHFFFAOYSA-N 5-(6-chloro-3,4-dihydro-2h-chromen-8-yl)-3-[1-(2,3-dihydro-1h-inden-2-yl)piperidin-4-yl]-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C1C2=CC=CC=C2CC1N(CC1)CCC1N(C(=O)O1)N=C1C1=CC(Cl)=CC2=C1OCCC2 LPUPVNNWASFIFG-UHFFFAOYSA-N 0.000 description 1
- OGPRQBADTNWSKY-UHFFFAOYSA-N 5-(6-chloro-3,4-dihydro-2h-chromen-8-yl)-3-[1-[4-[4-(dimethylamino)piperidin-1-yl]-4-oxobutyl]piperidin-4-yl]-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C1CC(N(C)C)CCN1C(=O)CCCN1CCC(N2C(OC(=N2)C=2C=3OCCCC=3C=C(Cl)C=2)=O)CC1 OGPRQBADTNWSKY-UHFFFAOYSA-N 0.000 description 1
- LKYLYFSTNNVQNS-UHFFFAOYSA-N 5-amino-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C1C(C(O)=O)=CC=C2N LKYLYFSTNNVQNS-UHFFFAOYSA-N 0.000 description 1
- SGPAPRPKRANLEF-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1-benzofuran-7-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC2=C1OCC2 SGPAPRPKRANLEF-UHFFFAOYSA-N 0.000 description 1
- HIDAFWCPNYVJAD-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-chromene-8-carboxylic acid Chemical compound C1CCOC2=C1C=C(Cl)C=C2C(=O)O HIDAFWCPNYVJAD-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010002758 Anticipatory anxiety Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000007555 cardiovascular defect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical class [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CLPRZDRHQSJNJT-UHFFFAOYSA-N methyl 4-amino-5-chloro-2-(cyclopropylmethoxy)benzoate Chemical compound COC(=O)C1=CC(Cl)=C(N)C=C1OCC1CC1 CLPRZDRHQSJNJT-UHFFFAOYSA-N 0.000 description 1
- ALYQFGBPEGLBLW-UHFFFAOYSA-N methyl 4-amino-5-chloro-2-methoxybenzoate Chemical compound COC(=O)C1=CC(Cl)=C(N)C=C1OC ALYQFGBPEGLBLW-UHFFFAOYSA-N 0.000 description 1
- VPUNONJHQKLMEF-UHFFFAOYSA-N methyl 5-chloro-2,3-dihydro-1-benzofuran-7-carboxylate Chemical compound COC(=O)C1=CC(Cl)=CC2=C1OCC2 VPUNONJHQKLMEF-UHFFFAOYSA-N 0.000 description 1
- XURXSJHLMYVRDF-UHFFFAOYSA-N methyl 6-chloro-3,4-dihydro-2h-chromene-8-carboxylate Chemical compound C1CCOC2=C1C=C(Cl)C=C2C(=O)OC XURXSJHLMYVRDF-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UDIULSPBXRJHEO-UHFFFAOYSA-N tert-butyl 4-[5-(5-chloro-2,3-dihydro-1-benzofuran-7-yl)-2-oxo-1,3,4-oxadiazol-3-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)OC(C=2C=3OCCC=3C=C(Cl)C=2)=N1 UDIULSPBXRJHEO-UHFFFAOYSA-N 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR95/13253 | 1995-11-09 | ||
| FR95/13252 | 1995-11-09 | ||
| FR9513253A FR2741070B1 (fr) | 1995-11-09 | 1995-11-09 | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique |
| FR9513252A FR2741069B1 (fr) | 1995-11-09 | 1995-11-09 | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique |
| FR9602663A FR2745574B1 (fr) | 1996-03-04 | 1996-03-04 | Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique |
| FR96/02663 | 1996-03-04 | ||
| PCT/FR1996/001730 WO1997017345A1 (fr) | 1995-11-09 | 1996-11-05 | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3? |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000500125A JP2000500125A (ja) | 2000-01-11 |
| JP2000500125A5 JP2000500125A5 (enExample) | 2004-10-21 |
| JP4263240B2 true JP4263240B2 (ja) | 2009-05-13 |
Family
ID=27253120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51791797A Expired - Fee Related JP4263240B2 (ja) | 1995-11-09 | 1996-11-05 | ５−フェニル−３−（ピペリジン−４−イル）−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体、及びその５−ｈｔ４又はｈ３レセプターリガンドとしての用途 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5929089A (enExample) |
| EP (1) | EP0863897B1 (enExample) |
| JP (1) | JP4263240B2 (enExample) |
| CN (1) | CN1077891C (enExample) |
| AR (1) | AR004708A1 (enExample) |
| AT (1) | ATE181328T1 (enExample) |
| AU (1) | AU707325B2 (enExample) |
| BG (1) | BG63463B1 (enExample) |
| BR (1) | BR9611311A (enExample) |
| CA (1) | CA2236357C (enExample) |
| CO (1) | CO4770968A1 (enExample) |
| CZ (1) | CZ287268B6 (enExample) |
| DE (1) | DE69602970T2 (enExample) |
| EE (1) | EE03487B1 (enExample) |
| ES (1) | ES2135934T3 (enExample) |
| GR (1) | GR3030823T3 (enExample) |
| HU (1) | HUP0001168A3 (enExample) |
| IL (1) | IL124364A (enExample) |
| MX (1) | MX9803696A (enExample) |
| NO (1) | NO309606B1 (enExample) |
| NZ (1) | NZ321626A (enExample) |
| PL (1) | PL186204B1 (enExample) |
| RU (1) | RU2167160C2 (enExample) |
| SI (1) | SI0863897T1 (enExample) |
| SK (1) | SK282335B6 (enExample) |
| TR (1) | TR199800827T2 (enExample) |
| TW (1) | TW371303B (enExample) |
| UA (1) | UA50748C2 (enExample) |
| WO (1) | WO1997017345A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| FR2762316B1 (fr) * | 1997-04-18 | 1999-12-17 | Sanofi Synthelabo | Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
| WO1998050383A1 (fr) * | 1997-05-06 | 1998-11-12 | Sanofi-Synthelabo | Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 |
| FR2763068B1 (fr) * | 1997-05-06 | 1999-06-04 | Synthelabo | Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
| GB9715816D0 (en) * | 1997-07-25 | 1997-10-01 | Black James Foundation | Histamine H receptor ligands |
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| AU755119B2 (en) | 1998-09-18 | 2002-12-05 | Alcon Laboratories, Inc. | Serotonergic 5HT2 agonists for treating glaucoma |
| WO2000064441A2 (en) * | 1999-04-28 | 2000-11-02 | Respiratorius Ab | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| CN1355698A (zh) * | 1999-06-15 | 2002-06-26 | 呼吸器有限公司 | 可用作治疗有关支气管收缩的机能障碍的药物的化合物 |
| US6638967B2 (en) | 2000-08-08 | 2003-10-28 | Ortho-Mcneil Phamraceutical, Inc. | Thiophene of furan pyrrolidine compounds |
| CA2418369A1 (en) | 2000-08-08 | 2002-02-14 | Richard Apodaca | Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| CZ2003686A3 (cs) * | 2000-08-08 | 2003-08-13 | Ortho Mcneil Pharmaceutical, Inc. | Neimidazolové aryloxypiperidiny |
| US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
| WO2003004480A2 (en) | 2001-07-02 | 2003-01-16 | Novo Nordisk A/S | Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| EP1434765B1 (en) * | 2001-09-14 | 2009-12-02 | High Point Pharmaceuticals, LLC | Substituted piperidines with selective binding to histamine h3-receptor |
| US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
| US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| JP4619655B2 (ja) | 2001-09-14 | 2011-01-26 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体 |
| US7064135B2 (en) | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
| WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
| JP2005511764A (ja) | 2001-12-14 | 2005-04-28 | アルコン，インコーポレイテッド | 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物 |
| US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
| GB0211230D0 (en) * | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EA200801607A1 (ru) | 2004-06-15 | 2008-10-30 | Пфайзер Инк. | Производные бензимидазолонкарбоновой кислоты |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| CN103110635A (zh) * | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
| DE602006011363D1 (de) * | 2005-12-01 | 2010-02-04 | Hoffmann La Roche | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer |
| ATE538116T1 (de) * | 2006-05-29 | 2012-01-15 | High Point Pharmaceuticals Llc | 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| DK2758394T3 (en) * | 2011-09-19 | 2015-04-20 | Suven Life Sciences Ltd | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055476A (en) * | 1990-08-13 | 1991-10-08 | Hoechst-Roussel Pharmaceuticals Incorporated | 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives |
| NZ243993A (en) * | 1991-08-20 | 1994-10-26 | Smithkline Beecham Plc | Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity |
| ES2135414T3 (es) * | 1991-09-12 | 1999-11-01 | Smithkline Beecham Plc | Antagonistas del receptor 5-ht4. |
| CA2129112A1 (en) * | 1992-02-06 | 1993-08-19 | Francis David King | Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists |
| GB9219163D0 (en) * | 1992-09-10 | 1992-10-28 | Smithkline Beecham Plc | Pharmaceuticals |
| JPH06157518A (ja) * | 1992-11-27 | 1994-06-03 | Yamanouchi Pharmaceut Co Ltd | 新規なオキサジアゾール誘導体又はその塩 |
-
1996
- 1996-11-05 JP JP51791797A patent/JP4263240B2/ja not_active Expired - Fee Related
- 1996-11-05 BR BR9611311A patent/BR9611311A/pt not_active IP Right Cessation
- 1996-11-05 TR TR1998/00827T patent/TR199800827T2/xx unknown
- 1996-11-05 SI SI9630092T patent/SI0863897T1/xx not_active IP Right Cessation
- 1996-11-05 AT AT96937390T patent/ATE181328T1/de active
- 1996-11-05 CA CA002236357A patent/CA2236357C/en not_active Expired - Fee Related
- 1996-11-05 EP EP96937390A patent/EP0863897B1/fr not_active Expired - Lifetime
- 1996-11-05 EE EE9800155A patent/EE03487B1/xx not_active IP Right Cessation
- 1996-11-05 DE DE69602970T patent/DE69602970T2/de not_active Expired - Lifetime
- 1996-11-05 ES ES96937390T patent/ES2135934T3/es not_active Expired - Lifetime
- 1996-11-05 UA UA98031589A patent/UA50748C2/uk unknown
- 1996-11-05 IL IL12436496A patent/IL124364A/xx not_active IP Right Cessation
- 1996-11-05 AU AU75001/96A patent/AU707325B2/en not_active Ceased
- 1996-11-05 PL PL96326671A patent/PL186204B1/pl not_active IP Right Cessation
- 1996-11-05 HU HU0001168A patent/HUP0001168A3/hu unknown
- 1996-11-05 SK SK599-98A patent/SK282335B6/sk not_active IP Right Cessation
- 1996-11-05 NZ NZ321626A patent/NZ321626A/xx not_active IP Right Cessation
- 1996-11-05 CN CN96198208A patent/CN1077891C/zh not_active Expired - Fee Related
- 1996-11-05 RU RU98110976/04A patent/RU2167160C2/ru not_active IP Right Cessation
- 1996-11-05 US US09/068,390 patent/US5929089A/en not_active Expired - Lifetime
- 1996-11-05 WO PCT/FR1996/001730 patent/WO1997017345A1/fr not_active Ceased
- 1996-11-05 CZ CZ19981421A patent/CZ287268B6/cs not_active IP Right Cessation
- 1996-11-07 TW TW085113594A patent/TW371303B/zh not_active IP Right Cessation
- 1996-11-08 CO CO96059097A patent/CO4770968A1/es unknown
- 1996-11-08 AR ARP960105098A patent/AR004708A1/es active IP Right Grant
-
1998
- 1998-04-28 BG BG102412A patent/BG63463B1/bg unknown
- 1998-05-07 NO NO982092A patent/NO309606B1/no not_active IP Right Cessation
- 1998-05-08 MX MX9803696A patent/MX9803696A/es unknown
-
1999
- 1999-07-20 GR GR990401913T patent/GR3030823T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2167160C2 (ru) | Производные 5-фенил-3-(пиперидин-4-ил)-1,3,4-оксадиазол-2(3н)-она, способ их получения, фармацевтическая композиция на их основе и лекарственное средство | |
| RU2186066C2 (ru) | Производные 5-арил-3-(8-азабицикло[3.2.1]окт-3-ил)-1,3,4-оксадиазол-2(3h)-она, способ их получения, лекарственное средство и фармацевтическая композиция | |
| HRP20030923A2 (en) | Novel piperidinecarboxamide derivatives, method for prreparing same and pharmaceutical compositions containing same | |
| JP4242929B2 (ja) | ３−（ピロリジン−３−イル）−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体および５−ｈｔ４リガンドとしての使用 | |
| KR100474454B1 (ko) | 5-ht₄또는h₃수용체리간드로서사용하기위한5-페닐-3-(피페리딘-4-일)-1,3,4-옥사디아졸-2(3h)-온유도체 | |
| HK1016165B (en) | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands | |
| MXPA99009506A (en) | 5-aryl-3-(8-azabicyclo(3.2.2)oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands | |
| FR2741069A1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique | |
| EP0980370A1 (fr) | Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 | |
| FR2741070A1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique | |
| FR2745574A1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique | |
| FR2763067A1 (fr) | Derives de 3-(1-azabicyclo[2.2.2] oct-3-ylalkyl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041229 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070808 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081201 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090122 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090203 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090212 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |